Literature DB >> 12226051

Prognostic factors in non-small cell lung cancer: a decade of progress.

Michael D Brundage1, Diane Davies, William J Mackillop.   

Abstract

STUDY
OBJECTIVES: To provide a systematic overview of the literature investigating patient and tumor factors that are predictive of survival for patients with non-small cell lung cancer (NSCLC), and to analyze patterns in the design of these studies in order to highlight problematic aspects of their design and to advocate for appropriate directions of future studies.
DESIGN: A systematic search of the MEDLINE database and a synthesis of the identified literature. MEASUREMENTS AND
RESULTS: The database search (January 1990 to July 2001) was carried out combining the MeSH terms prognosis and carcinoma, nonsmall cell lung. Eight hundred eighty-seven articles met the search criteria. These studies identified 169 prognostic factors relating either to the tumor or the host. One hundred seventy-six studies reported multivariate analyses. Concerning 153 studies reporting a multivariate analysis of prognostic factors in patients with early-stage NSCLC, the median number of patients enrolled per study was 120 (range, 31 to 1,281 patients). The median number of factors reported to be significant in univariate analyses was 4 (range, 2 to 14 factors). The median number of factors reported to be significant in multivariate analyses per study was 2 (range, 0 to 6 factors). The median number of studies examining each prognostic factor was 1 (range, 1 to 105 studies). Only 6% of studies addressed clinical outcomes other than patient survival.
CONCLUSIONS: While the breadth of prognostic factors studied in the literature is extensive, the scope of factors evaluated in individual studies is inappropriately narrow. Individual studies are typically statistically underpowered and are remarkably heterogeneous with regard to their conclusions. Larger studies with clinically relevant modeling are required to address the usefulness of newly available prognostic factors in defining the management of patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226051     DOI: 10.1378/chest.122.3.1037

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  160 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  NDRG1/Cap43 overexpression in tumor tissues and serum from lung cancer patients.

Authors:  D Wang; X Tian; Y Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-22       Impact factor: 4.553

4.  Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.

Authors:  Tomohiro Yazawa; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Yoichi Ohtaki; Jun Atsumi; Kai Obayashi; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Izumi Takeyoshi
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

5.  Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.

Authors:  Maristela L Onozato; Alexandra E Kovach; Beow Y Yeap; Vicente Morales-Oyarvide; Veronica E Klepeis; Swathi Tammireddy; Rebecca S Heist; Eugene J Mark; Dora Dias-Santagata; A John Iafrate; Yukako Yagi; Mari Mino-Kenudson
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

6.  Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.

Authors:  Helga Sertić Milić; Ana Franjević; Gordana Bubanović; Ante Marušić; Igor Nikolić; Igor Puljić
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

7.  PET/CT Assessment of Response to Therapy: Tumor Change Measurement, Truth Data, and Error.

Authors:  Paul E Kinahan; Robert K Doot; Michelle Wanner-Roybal; Luc M Bidaut; Samuel G Armato; Charles R Meyer; Geoffrey McLennan
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

8.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

Authors:  Ramon Andrade de Mello; Filipa Soares Pires; Dânia Sofia Marques; Júlio Oliveira; Ana Rodrigues; Marta Soares; Isabel Azevedo; Ana Peixoto; Catarina Santos; Carla Pinto; Venceslau Hespanhol; Manuel R Teixeira; Teresina Amaro; Henrique Queiroga; António Araújo
Journal:  Tumour Biol       Date:  2012-07-29

9.  Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trial.

Authors:  Sandra Pauls; Andreas K Buck; Gisela Halter; Felix M Mottaghy; Rainer Muche; Christina Bluemel; Susanne Gerstner; Stefan Krüger; Gerhard Glatting; Ludger Sunder-Plassmann; Peter Möller; Hans-Jürgen Brambs; Sven N Reske
Journal:  Mol Imaging Biol       Date:  2008-01-16       Impact factor: 3.488

Review 10.  Lung cancer.

Authors:  Alan Neville
Journal:  BMJ Clin Evid       Date:  2009-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.